Faron Pharmaceuticals Oy (LSE:FARN) — Market Cap & Net Worth
Market Cap & Net Worth: Faron Pharmaceuticals Oy (FARN)
Faron Pharmaceuticals Oy (LSE:FARN) has a market capitalization of $575.13K (GBX4.73 Billion) as of May 5, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30496 globally and #889 in its home market, demonstrating a -4.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Faron Pharmaceuticals Oy's stock price GBX41.50 by its total outstanding shares 113902670 (113.90 Million). Analyse how efficiently does Faron Pharmaceuticals Oy generate cash to see how efficiently the company converts income to cash.
Faron Pharmaceuticals Oy Market Cap History: 2015 to 2026
Faron Pharmaceuticals Oy's market capitalization history from 2015 to 2026. Data shows change from $3.39 Million to $575.13K (-16.61% CAGR).
Index Memberships
Faron Pharmaceuticals Oy is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.14 Million | 0.06% | #209 of 722 |
Weight: Faron Pharmaceuticals Oy's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Faron Pharmaceuticals Oy Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Faron Pharmaceuticals Oy's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
40.47x
Faron Pharmaceuticals Oy's market cap is 40.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.39 Million | $520.00K | -$6.19 Million | 6.53x | N/A |
| 2016 | $3.67 Million | $1.15 Million | -$9.29 Million | 3.18x | N/A |
| 2017 | $11.08 Million | $1.50K | -$21.06 Million | 7414.52x | N/A |
| 2018 | $769.00K | $19.00K | -$20.09 Million | 40.47x | N/A |
Competitor Companies of FARN by Market Capitalization
Companies near Faron Pharmaceuticals Oy in the global market cap rankings as of May 5, 2026.
Key companies related to Faron Pharmaceuticals Oy by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Faron Pharmaceuticals Oy Historical Marketcap From 2015 to 2026
Between 2015 and today, Faron Pharmaceuticals Oy's market cap moved from $3.39 Million to $ 575.13K, with a yearly change of -16.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX575.13K | -76.94% |
| 2025 | GBX2.49 Million | -12.20% |
| 2024 | GBX2.84 Million | -32.79% |
| 2023 | GBX4.23 Million | +1.67% |
| 2022 | GBX4.16 Million | +10.09% |
| 2021 | GBX3.78 Million | +4.81% |
| 2020 | GBX3.60 Million | -0.95% |
| 2019 | GBX3.64 Million | +373.07% |
| 2018 | GBX769.00K | -93.06% |
| 2017 | GBX11.08 Million | +201.89% |
| 2016 | GBX3.67 Million | +8.16% |
| 2015 | GBX3.39 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Faron Pharmaceuticals Oy was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $575.13K USD |
| MoneyControl | $575.13K USD |
| MarketWatch | $575.13K USD |
| marketcap.company | $575.13K USD |
| Reuters | $575.13K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more